Tag
This UK prospective study assesses pregnancy outcomes in women with preexisting cardiomyopathy, revealing generally favorable maternal and neonatal results with low cardiac complication rates and no maternal deaths.
A prospective study reveals that ultra-rare cardiomyopathy gene variants significantly increase risk for early heart failure in infants with hypoplastic left heart syndrome, highlighting potential for genetic risk stratification and precisi
This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 tri
This study reveals that bisphenol F exposure aggravates cardiomyopathy under hemodynamic stress through gut microbiota metabolism, highlighting a novel gut-heart axis involving N-acetylputrescine and potential therapeutic targets.
This review synthesizes evidence from a pioneering nonrandomized trial demonstrating that intravenous AAVrh.10hFXN gene therapy is safe and may improve cardiac outcomes in Friedreich ataxia cardiomyopathy, highlighting translational advance
Genetic variants enriched in individuals of African ancestry confer increased risk of cardiomyopathy and arrhythmias, with cardiovascular risk factors amplifying this risk. Large biobank studies enable reclassification of key variants and h
A large registry study found that genetic cardiomyopathy risk varies by sex, age, and gene. TTN truncating variants were more common and earlier in males, while DSP and non-TTN sarcomeric variants were more common in females.
Gene therapy for cardiomyopathy is moving from concept to clinic, but durable benefit will depend on solving delivery, immunogenicity, cargo, and safety barriers in the failing human heart.
The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in
A large-scale study from the Penn Medicine BioBank demonstrates that polygenic risk scores for hypertrophic and dilated cardiomyopathies act as bidirectional modifiers, influencing the clinical expression of rare pathogenic variants and off
In 718 patients with pathogenic/likely pathogenic LMNA variants, truncating variants carried higher risk of malignant ventricular arrhythmia independent of position, while missense variants in the tail domain and exons 7–12 had lower arrhyt
A large multi-cohort genetic analysis shows that both rare monogenic variants and a high polygenic score for dilated cardiomyopathy (DCM) are enriched in peripartum, alcohol-induced, and cancer therapy–related cardiomyopathies, supporting a
The nationwide SCD‑PROTECT study (n=19,598) found substantial early risk of sustained VT/VF in newly diagnosed ischaemic and non‑ischaemic cardiomyopathy; wearable cardioverter‑defibrillators (WCDs) delivered life‑saving therapy with low in
In a large UK Biobank cohort, accelerometer-measured moderate‑to‑vigorous physical activity (100–400 min/week) was associated with lower cardiovascular risk and no excess arrhythmic or cardiomyopathy onset among genotype‑positive phenotype‑
